Investor Presentaiton

Royalty Pharma capital critical to enabling biotech growth Biohaven raised ~$3.2bn in capital (¹) Cytokinetics raised ~$2.0bn in capital(2) BioCryst raised ~$1.3bn in capital(3) (May 2017 - YTD 2022) Pfizer partnership Royalty Pharma Partnership Debt 23% 16% Other 26% (June 2013 YTD 2022) Royalty Pharma Partnership Debt 33% 27% 6% 35% 34% Debt Equity Equity (December 2012 - YTD 2022) Other Royalty Pharma Partnership 25% 12% 25% 38% Equity Royalty funding expected to be an increasingly important mix of total capital raised by biotech companies ROYALTY PHARMA (1) Capital raised since Biohaven's May, 2017 IPO. Only includes upfront payment from Pfizer partnership. (2) Capital raised since Cytokinetics expanded license agreement with Amgen, June 12, 2013. (3) Since BioCryst's December 2012 corporate restructuring to focus strategy on advancing hereditary angioedema program. 74

View entire presentation